Impact of Homeoprophylactic Arsenicum album 30c on COVID-19 Vaccine-related Adverse Events: A Combined Retrospective–Prospective Cohort Study
Auswirkung von homeoprophylaktischem Arsenicum album 30C auf COVID-19-Impfnebenwirkungen: kombinierte retrospektiv-prospektive Kohortenstudie
Homeopathy · 01.02.2026 · 115 (01) · 014-023
DOI: 10.1055/a-2512-9763 ↗Auf einen Blick
Bei 1.737 Geimpften waren COVID-19-Impfnebenwirkungen unter Arsenicum album 30C seltener als ohne homöopathische Intervention. Der Unterschied war statistisch signifikant.
Fragestellung
Vermindert homeoprophylaktisches Arsenicum album 30C COVID-19-Impfnebenwirkungen?
Methode
Kombinierte retrospektiv-prospektive Kohortenstudie in urbanen Slums von New Delhi; Vergleich von Teilnehmenden mit Arsenicum album 30C und ohne homöopathische Intervention.
Ergebnisse
1.737 Teilnehmende; 436 in der Medikamenten- und 1.301 in der Kontrollkohorte. Gesamt-OR für AEs nach einer der beiden Dosen: 0,29 (95 %-KI 0,23–0,37); adjustiert 0,30 (95 %-KI 0,24–0,39).
Schlussfolgerung der Autor:innen
Die frühere Anwendung von Arsenicum album 30C reduzierte laut Autor:innen COVID-19-Impfnebenwirkungen signifikant.
Kernaussagen
- AEs nach COVID-19-Impfung waren unter AA30 seltener
- Gesamt-OR 0,29 (95 %-KI 0,23–0,37)
- Auch nach 1. und 2. Dosis zeigte sich ein Schutzsignal
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Kohortenstudie in der Zeitschrift Homeopathy, erschienen am 01.02.2026. Verfasst von Debadatta Nayak und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, India. Hauptthemen laut MEDLINE: COVID-19 Vaccines, COVID-19, Homeopathy. Die Arbeit nennt 46 Literaturangaben.
Themen: Patientensicherheit
Abstract (Originalsprache)
Arsenicum album 30C (AA30) was recommended by the Government of India for the prevention of coronavirus infection. In the wake of the reporting of COVID-19 vaccine-related adverse events (AEs) and consequent vaccine hesitancy, this study was undertaken to assess the impact of homeo-prophylactic AA30 on COVID-19 vaccine-related AEs. This was a combined retrospective–prospective cohort study that included participants who had been enrolled in an ongoing prospective, parallel cohort study being conducted in urban slums of New Delhi and who had received either or both doses of the COVID-19 vaccine. The reporting of COVID-19 vaccine-related AEs was compared between a cohort that had been receiving homeopathic AA30 as a prophylactic for influenza-like/COVID-like illness with one in which no homeopathic intervention was provided. A total of 1,737 participants who received either or both doses of vaccination for COVID-19 were included in the study, out of whom 436 participants were from the medicine cohort (MC) and 1,301 were from the control cohort (CC). Overall odds of developing AEs after either dose of COVID-19 vaccine in MC as compared with CC was found to be statistically significantly lower (overall crude OR = 0.29, 95% confidence interval [CI] = 0.23 to 0.37; p = 0.0001). The adjusted OR after accounting for age, sex, co-morbidities and vaccine type was 0.30 (95% CI = 0.24 to 0.39; p = 0.0001). The protective effect of the medicine against post-vaccination AEs was evident after the first dose as well as after the second dose, with overall crude OR being 0.37 (95% CI = 0.29 to 0.48; p = 0.0001) and 0.28 (95% CI = 0.19 to 0.41; p = 0.0001) respectively. Prior use of the homeopathic medicine AA30 was able to significantly reduce COVID-19 vaccine-related AEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Epidemic Cell, Central Council for Research in Homoeopathy, New Delhi, India.
- Department of Clinical Research, Central Council for Research in Homoeopathy, New Delhi, India.
- Clinical Research Unit for Homoeopathy, Under the Central Council for Research in Homoeopathy, Civil Hospital, Aizawl, Mizoram, India.
- Department of Clinical Research, Clinical Research Unit for Homoeopathy, Sri Vijaya Puram, Andaman & Nicobar Islands, India.
- Department of Health & Family Welfare (AYUSH), Government of West Bengal, Kolkata, West Bengal, India.
- Department of Practice of Medicine, State K.G.K. Homoeopathic Medical College and Hospital, Moradabad, Uttar Pradesh, India.
ORCID-Profile: Debadatta Nayak
Zitieren
APA
Nayak, D., Bhalla, R., Kaur, L., Bansal, D., Singh, S., Bagdi, N., Michael, J., Chaudhuri, A., Tyagi, L., Makhija, B., Madaan, S., Das, D., Shukla, I., Sanyal, S., Saleem, K. S., & Yadav, A. (2026). Impact of Homeoprophylactic Arsenicum album 30c on COVID-19 Vaccine-related Adverse Events: A Combined Retrospective–Prospective Cohort Study. Homeopathy, 115(01), 014-023. https://doi.org/10.1055/a-2512-9763
Vancouver
Nayak D, Bhalla R, Kaur L, Bansal D, Singh S, Bagdi N, et al. Impact of Homeoprophylactic Arsenicum album 30c on COVID-19 Vaccine-related Adverse Events: A Combined Retrospective–Prospective Cohort Study. Homeopathy. 2026;115(01):014-023. doi:10.1055/a-2512-9763
BibTeX
@article{Nayak2026,
author = {Nayak, Debadatta and Bhalla, Ruchika and Kaur, Lovepreet and Bansal, Divya and Singh, Smita and Bagdi, Navita and Michael, James and Chaudhuri, Abhishek and Tyagi, Lalit and Makhija, Bhavna and Madaan, Shikha and Das, Deblina and Shukla, Indu and Sanyal, Srimonti and Saleem, Khan Sheeba and Yadav, Ajay},
title = {Impact of Homeoprophylactic Arsenicum album 30c on COVID-19 Vaccine-related Adverse Events: A Combined Retrospective–Prospective Cohort Study},
journal = {Homeopathy},
year = {2026},
volume = {115},
number = {01},
pages = {014--023},
doi = {10.1055/a-2512-9763}
}
EUVIMED